Local and systemic antioxidants in preeclamptic pregnant women with and without Periodontitis

AIMS AND OBJECTIVES :                         To investigate the total antioxidant capacity and malondialdehyde level in serum & gingival crevicular fluid in preeclamptic and normotensive pregnant women with and without periodontal disease METHODS:                         A total of 60 pregnant patients whose age ranging from 20 - 35 years attending the Department of gynecology Rajah Muthiah Medical College and Hospital were selected for the present study and were divided into four groups as PREECLAMPTIC PREGNANT WOMEN WITH PERIODONTAL DISEASE, PREECLAMPTIC WITHOUT PERIODONTITIS, NORMOTENSIVE PREGNANT WOMEN  WITH PERIODONTITIS AND NORMOTENSIVE WITHOUT PERIODONTITIS.                         Following clinical examination Gingival crevicular fluid and blood sample was collected to analyze total antioxidant capacity and malondialdehyde levels. RESULTS:                          Preeclamptic pregnant women had more periodontal involvement than normotensive pregnant women. The serum and gingival crevicular fluid total antioxidant capacity was lower in preeclamptic women with periodontal involvement than the normotensive and those without periodontitis whereas the levels of serum and gingival crevicular fluid malondialdehyde levels were higher in Preeclamptic Periodontitis individuals when compared with normotensive and those without Periodontitis. CONCLUSION Preeclamptic pregnant women have reduced antioxidants and increased oxidative stress and maternal Periodontal disease could worsen the condition.     KEY WORDS: Antioxidants,Periodontitis, Preeclampsia, Oxidative stress   Total word count- 192 word

Design and development of a noninvasive ocular pressure estimator

Significance: A snapshot intraocular pressure (IOP) is ineffective in identifying the IOP peak and fluctuation, especially during sleep. Since IOP variability play a significant role in the progression of glaucoma, 34 monitoring the IOP, especially during sleep is essential to capture the dynamic nature of IOP. Purpose: We aimed to design an ocular pressure estimator (OPE) that can reliably and accurately measure the IOP non-invasively over closed eyelid condition. Methods: OPE works on the principle that the external pressure applied by raising the intraocular pressure of the eyeball is transmitted through a compressible septum to the pressure sensor, thus recording the IOP. A fluid-filled pouch with a pressure sensor was placed over a rubber glove mimicking the eyelid (septum), covering the cornea of enucleated goat eyeballs. A pressure controlled setup was connected to a goat cadaver eye which was validated by a rebound tonometer. Cannulation of eyeballs through the lower limbus had the least difference from the control setup values documented using rebound tonometer, compared to cannulation through the optic nerve. Intraocular pressures ranging from 3–30 mmHg was induced, and the outputs recorded using OPE were amplified and recorded for 10 minutes (n=10 eyes). We stratified the randomization of the number of times and the induced pressures. Results: The measurements recorded were found to be linear when measured against an intraocular pressure range of 3–30 mmHg. The device has excellent reliability (Intraclass correlation coefficient 0.998). The repeatability coefficient and coefficient of variations were 4.24 (3.60–4.87) and 8.61% (7.33–9.90), respectively. The overall mean difference ±SD between induced IOP and the OPE was 0.22 ± 3.50 (95% confidence interval: -0.35, 0.79) mmHg across all IOP ranges. Conclusion: OPE offers a promising approach for reliably and accurately measuring IOP and its fluctuation non invasively under condition mimicking closed eye

Novel CuO/chitosan nanocomposite thin film: Facile hand-picking recoverable, efficient and reusable heterogeneous photocatalyst

The present work demonstrates a new simple hand-picking technique for the 100% recovery of a photocatalyst. CuO nanospheres were synthesized by a simple wet chemical method and were subsequently embedded into the biopolymer matrix (chitosan) under mild conditions by the solution cast method and its photocatalytic application towards the degradation of organic pollutants was measured for the first time. The crystal structure, optical properties, surface and bulk morphology were discussed in detail. ICP-OES analysis showed 3.025% copper embedded in the chitosan (CS) matrix. Efficiency of the CuO/chitosan was evaluated against the degradation of rhodamine B dye as a probe. The combination of CuO nanospheres with chitosan leads to the higher efficiency of up to 99% degradation of the dye with 60 minutes of irradiation. This may be attributed to many features such as the slow electron hole pair recombination rate of nanosized CuO in the biopolymer matrix, the large surface area of the CuO and the high adsorption efficiency of the chitosan. The major advantage of this present protocol is that it is not only restricted to azo type dyes but can also be adopted for different kinds of organic pollutants. For all the types of organic contaminants tested, the CuO/chitosan nanocomposite thin film photocatalyst showed excellent activity. The facile hand-picking recovery and recyclability of this novel thin film likely opens up a new straightforward strategy in the effective photocatalytic degradation of organic contaminants

Effect of wafer level packaging, silicon substrate and board material on gigabit board-silicon-board data transmission

Proceedings - Electronic Components and Technology Conference21506-1512PECC

System-on-a-Package (SOP) Substrate and Module with Digital, RF and Optical Integration

The Packaging Research Center has been developing next generation system-on-a-package (SOP) technology with digital, RF, and optical system integration on a single package. SOP aims to utilize the best of on-chip SOC integration and package integration to achieve highest system performance at the lowest cost. The microminiaturized multifunctional SOP package is highly integrated and fabricated on large area substrates similar to the wafer-to-IC concept. In addition to novel mixed signal design methodologies, SOP research at PRC is targeted at developing enabling technologies for package level integration including ultra-high density wiring, embedded passive components, embedded optical interconnects, wafer level packaging and fine pitch assembly. Several of these enabling technologies have been recently integrated into the first successful system level demonstration of SOP technology using the Intelligent Network Communicator (INC) testbed. This paper reports on the latest INC and SOP testbed results at the PRC and provides an insight into the future SOP integration strategy for convergent microsystems. The focus of this paper is on integration of materials, processes and structures in a single package substrate for System-on-a-Package (SOP) implementation. I

Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study

Abstract Background: Tenalisib (RP6530), a highly selective PI3K δ/γ and SIK3 inhibitor has shown promising activity as a single agent in T Cell lymphoma (TCL) and a differentiated safety profile (Huen A et al., Cancers,2020). In vitro studies in TCL cell lines showed synergistic activity when tenalisib was combined with romidepsin. A Phase I/II study of tenalisib in combination with romidepsin was designed to assess safety, pharmacokinetics, and efficacy in patients with relapsed/refractory (R/R) TCL peripheral (PTCL) and cutaneous T cell lymphoma (CTCL) (NCT03770000). Methods: This was a multi-center, open label study. We performed a Phase I, 3+3 dose escalation study to determine the MTD/recommended Phase II dose (RP2D), and a dose expansion study in both the subtypes separately (PTCL and CTCL). Patients received tenalisib at doses ranging from 400-800 mg BID (fasting), orally in combination with romidepsin at doses ranging from 12-14 mg/m 2, intravenously, given on Days 1,8 and 15 of a 28-day cycle. Results: Thirty-three patients (16 PTCL and 17 CTCL) who received more than 1 prior therapy were enrolled in the study; 9 in dose escalation and 24 in dose expansion. Of the 33 patients, 64% were refractory to their last therapy. The median number of prior therapies was 3. Most patients (67%) had stage III/IV disease at time of enrolment. No dose limiting toxicity (DLT) was reported during dose escalation; tenalisib 800 mg BID with romidepsin 14 mg/m 2 (given on Days 1, 8, and 15) was chosen as the RP2D. The most frequent treatment emergent adverse events (TEAEs) were nausea (All: 73% and ≥G3:0%), thrombocytopenia (All:57% and ≥G3:21%), fatigue (All: 54% and ≥G3:6%), AST elevation (All:33% and ≥G3:6%) ALT elevation (All:27% and ≥G3:18%), neutropenia (All: 27% and ≥G3:15%), vomiting (All:27% and ≥G3:0%), decreased appetite (All: 27% and ≥G3:0%). There were no unexpected TEAEs. Among CTCL patients, five related TEAEs led to drug discontinuation were sepsis, ALT elevation, GGT elevation, rash, and dysgeusia. None of the PTCL patients discontinued the study drug due to related TEAEs. Incidences of TEAEs leading to drug interruption (72%) and dose reduction (45%) of any the drugs in the combination were similar in PTCL and CTCL groups. Based on C max and AUC, dose proportional exposure of tenalisib was observed from doses 400-800 mg BID. Co-administration of romidepsin with tenalisib did not significantly alter the PK of either agent. Of the 33 patients enrolled, 27 (12 PTCL and 15 CTCL) who received at least 1 dose of study drug and provided at least 1 post-baseline efficacy assessment were considered evaluable for efficacy as per protocol. The overall response rate (ORR) was of 63%; 7 (26%) patients achieved CR and 10 (37%) patients had PR (Table 1). The median duration of response (DoR) was 5.03 months (range: 2.16 months-Not Reached). In twelve evaluable PTCL patients, the ORR was 75% with 6 CR (50%) and 3 PR (25%). Among 15 evaluable CTCL patients, 8 responded with an ORR of 53.3%, 1 CR (6.7%) and 7 PR (46.7%). The median DoR was 5.03 (range: 2.16 months-Not Reached) for PTCL and 3.8 months (1.9-18.86) for CTCL. Three of the six (50%) PTCL patients with CR were bridged to transplant. Six patients who benefitted with the treatment and completed the protocol were enrolled in an open-label compassionate medication study after Cycle 7 and are being followed up. Conclusions: The combination of tenalisib and romidepsin demonstrates a favorable safety profile and promising anti-tumor activity in patients with R/R TCL. Based on these encouraging results, further development of this combination in PTCL patients in being planned. Figure 1 Figure 1. Disclosures Huen: Rhizen: Research Funding; Elorac: Research Funding; Kyowa Kirin: Research Funding; Tillium: Research Funding; Innate: Research Funding; Galderma: Research Funding; Miragen: Research Funding. Ai: Kymria, Kite, ADC Therapeutics, BeiGene: Consultancy. Feldman: Alexion, AstraZeneca Rare Disease: Honoraria, Other: Study investigator. Alderuccio: ADC Therapeutics: Consultancy, Research Funding; Oncinfo / OncLive: Honoraria; Puma Biotechnology: Other: Family member; Inovio Pharmaceuticals: Other: Family member; Agios Pharmaceuticals: Other: Family member; Forma Therapeutics: Other: Family member. Kuzel: Cardinal Health: Membership on an entity's Board of Directors or advisory committees; Exelixis: Membership on an entity's Board of Directors or advisory committees; Genomic Health: Membership on an entity's Board of Directors or advisory committees; Sanofi-Genzyme Genomic Health Tempus laboratories Bristol Meyers Squibb: Honoraria; Abbvie: Other; Curio Science: Membership on an entity's Board of Directors or advisory committees; AmerisourceBergen Corp: Membership on an entity's Board of Directors or advisory committees; CVS: Membership on an entity's Board of Directors or advisory committees; Tempus Laboratories: Membership on an entity's Board of Directors or advisory committees; Bristol Meyers Squibb: Membership on an entity's Board of Directors or advisory committees; Merck: Other: Data Monitoring Committee Membership; Amgen: Other: Data Monitoring Committee Membership; SeaGen: Other: Data Monitoring Committee Membership; Medpace: Other: Data Monitoring Committee Membership